This is an important and fundamental question because despite the identification of tissue transglutaminase (tTG) as a major autoantigen targeted by antibodies in CeD [12] (the basis for why it is widely labelled an autoimmune disorder), no study to date has demonstrated that anti-tTG antibodies are pathogenic. This evidence concerns the gene TGM2 and cranioectodermal dysplasia.